SynthesisGastroenterology2018
Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases.
Synthesis in Gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 159 citations in OpenAlex.
- Glycomic Signatures of Plasma IgG Improve Preoperative Prediction of the Invasiveness of Small Lung Nodules.Molecules (Basel, Switzerland) · 2019Trial
- Glycosylation in gut-brain communication: from the intestinal barrier and microbiota to immune and neural signaling.Gut microbes · 2026Review
- Large glycomics datasets as a tool to understand the function of glycans.Nature chemical biology · 2026Review
- Intestinal Fucosylation: A Key Regulatory Hub in Homeostasis and Disease Pathogenesis.Biomolecules · 2026Review
- CSF-Compartmentalized Antibody Glycoprofiles in NMDAR Encephalitis Associate with Etiology and Functional Recovery.Annals of neurology · 2026Article
- Mucosal glycans: key drivers of the development of inflammatory bowel disease and a potential new therapeutic target.Nature reviews. Gastroenterology & hepatology · 2026Review
- Microbial Consortia-Immunoglobulin G Glycosylation Combination Scores Identify Severe Hepatic Steatosis and Significant Fibrosis in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.Clinical and translational gastroenterology · 2026Article
- Assessment of IgG N-Glycan patterns in adult patients with immune thrombocytopenia and healthy individuals.Glycoconjugate journal · 2026Article
- Not all antibodies are created equal: total IgG glycosylation and severity of antibody-mediated rejection in kidney transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Fucose metabolism as a central axis linking inflammation, immunity, and cancer in the gut.Frontiers in immunology · 2026Review
- Immunoglobulin GFrontiers in immunology · 2026Article
- Antibody glycosylation in neuroimmune diseases.Journal of translational medicine · 2025Review
- Glycomics in Human Diseases and Its Emerging Role in Biomarker Discovery.Biomedicines · 2025Review
- ILC3s regulate the gut microbiota via host intestinal galactosylation to limit pathogen infection in mice.Nature microbiology · 2025Article
- Profiling of IgG N-glycosylation for axial spondyloarthritis and other rheumatic diseases.Arthritis research & therapy · 2025Article
- Aberrant glycosylation patterns as potential biomarkers for diagnosis and disease progression in bullous pemphigoid.Frontiers in immunology · 2025Article
- N-glycosylation patterns of plasma immunoglobulin G in anti-synthetase syndrome disease.Frontiers in immunology · 2025Article
- The potential applications of peptide-loading complex in cancer treatment.Frontiers in immunology · 2025Review
- Bovine Colostrum in Pediatric Nutrition and Health.Nutrients · 2024Review
- Immunomolecular and reactivity landscapes of gut IgA subclasses in homeostasis and inflammatory bowel disease.The Journal of experimental medicine · 2024Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 11 institutions in 5 countries.
Funding
Abstract
BACKGROUND AND
aimsCauses of inflammatory bowel diseases are not well understood and the most prominent forms, Crohn's disease (CD) and ulcerative colitis (UC), are sometimes hard to distinguish. Glycosylation of IgG has been associated with CD and UC. IgG Fc-glycosylation affects IgG effector functions. We evaluated changes in IgG Fc-glycosylation associated with UC and CD, as well as with disease characteristics in different patient groups.
methodsWe analyzed 3441 plasma samples obtained from 2 independent cohorts of patients with CD (874 patients from Italy and 391 from the United States) or UC (1056 from Italy and 253 from the US and healthy individuals [controls]; 427 in Italy and 440 from the United States). IgG Fc-glycosylation (tryptic glycopeptides) was analyzed by liquid chromatography coupled to mass spectrometry. We analyzed associations between disease status (UC vs controls, CD vs controls, and UC vs CD) and glycopeptide traits, and associations between clinical characteristics and glycopeptide traits, using a logistic regression model with age and sex included as covariates.
resultsPatients with CD or UC had lower levels of IgG galactosylation than controls. For example, the odds ratio (OR) for IgG1 galactosylation in patients with CD was 0.59 (95% confidence interval [CI], 0.51-0.69) and for patients with UC was 0.81 (95% CI, 0.71-0.92). Fucosylation of IgG was increased in patients with CD vs controls (for IgG1: OR, 1.27; 95% CI, 1.12-1.44), but decreased in patients with UC vs controls (for IgG23: OR, 0.72; 95% CI, 0.63-0.82). Decreased galactosylation associated with more severe CD or UC, including the need for surgery in patients with UC vs controls (for IgG1: OR, 0.69; 95% CI, 0.54-0.89) and in patients with CD vs controls (for IgG23: OR, 0.78; 95% CI, 0.66-0.91).
conclusionsIn a retrospective analysis of plasma samples from patients with CD or UC, we associated levels of IgG Fc-glycosylation with disease (compared to controls) and its clinical features. These findings could increase our understanding of mechanisms of CD and UC pathogenesis and be used to develop diagnostics or guide treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.